The Nasal Spray Is a CGRP-Inhibitor
Calcitonin gene-related peptides (CGRP) play a key role in the development of many migraines. CGRP release is a feature in migraines preceding the painful attack. In addition, intravenous injection of CGRP can trigger migraine-like attacks in migraineurs.
CGRP also seems to play a role in sensitization. Sensitization is when your nervous system becomes conditioned to experience pain, even from stimuli that shouldn’t be painful. Sensitization contributes to many chronic pain types, including migraine and TMJ.
When CGRP inhibitors were introduced, developers hoped they would offer unequaled migraine relief. CGRP inhibitors are a game-changer for some people, but, as in this trial, they may only provide relief for 50% or less of migraineurs. If you have tried CGRP inhibitors without success, the new nasal spray might not work for you. In a related development, some researchers think they’ve identified a test to show which people will respond to CGRP inhibitors.
We don’t know if CGRP inhibitors can reduce sensitization and combat chronic pain.
CGRP is one of the pathways by which TMJ can trigger migraines. TMJ treatment in Lee’s Summit offers a drug-free way to target the CGRP pathway. Because this is only one of the migraine causes affected by TMJ, many migraineurs who don’t benefit from CGRP inhibitors might still benefit from TMJ treatment. In other words, TMJ treatment can help both those who do–and do not–get results from CGRP inhibitors.